Productivity losses associated with cardiovascular disease: a systematic review

References

• World Health Organization. The top 10 causes of death – factsheet number 310. Geneva: World Health Organization; 2014.
   Google Scholar
• Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics—2016 update. Circulation. 2015;133(4):e38–e360.
   PubMed Web of Science ®Google Scholar
• Townsend N, Nichols M, Scarborough P, et al. Cardiovascular disease in Europe – epidemiological update 2015. Eur Heart J. 2015;36(40):2696–2705.
   PubMed Web of Science ®Google Scholar
• Taylor F, Huffman MD, Macedo A, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013;Issue:1.
   Google Scholar
• Grover SA, Ho V, Lavoie F, et al. The importance of indirect costs in primary cardiovascular disease prevention: can we save lives and money with statins? Arch Intern Med. 2003;163(3):333–339.
   PubMedGoogle Scholar
• Nichols M, Townsend N, Luengo-Fernandez R, et al. European cardiovascular disease statistics. Vol. 2012. Brussels: European Heart Network; 2012
   Google Scholar
• The World Bank. Consumer price index (2010 = 100). The world bank. 2016. http://data.worldbank.org/indicator/FP.CPI.TOTL. [cited 2016 Mar 23]
   Google Scholar
• Sasser AC, Rousculp MD, Birnbaum HG, et al. Economic burden of osteoporosis, breast cancer, and cardiovascular disease among postmenopausal women in an employed population. Women Health Iss. 2005;15(3):97–108.
   PubMed Web of Science ®Google Scholar
• Goetzel RZ, Long SR, Ozminkowski RJ, et al. Health, absence, disability, and presenteeism cost estimates of certain physical and mental health conditions affecting U.S. employers. J Occup Environ Med. 2004;46:398–412.
   PubMed Web of Science ®Google Scholar
• Lamb CE, Ratner PH, Johnson CE, et al. Economic impact of workplace productivity losses due to allergic rhinitis compared with select medical conditions in the United States from an employer perspective. Curr Med Res Opin. 2006;22(6):1203–1210.
   PubMed Web of Science ®Google Scholar
• Song X, Huse DM, Williams SA, et al. A projection of the impact of lipid-lowering therapy on high-risk employee disability and medical costs. J Occup Environ Med. 2006;48(10):1014–1022.
   PubMed Web of Science ®Google Scholar
• Greene BL, Miller JD, Brown TM, et al. Economic impact of the BP downshift program on blood pressure control among commercial driver license employees. J Occup Environ Med. 2009;51(5):542–553.
   PubMed Web of Science ®Google Scholar
• Collins JJ, Baase CM, Sharda CE, et al. The assessment of chronic health conditions on work performance, absence, and total economic impact for employers. J Occup Environ Med. 2005;47(6):547–557.
   PubMed Web of Science ®Google Scholar
• Bunn III WB, Stave GM, Downs KE, et al. Effect of smoking status on productivity loss. J Occup Environ Med. 2006;48(10):1099–1108.
   PubMed Web of Science ®Google Scholar
• Heidenreich PA, Trogdon JG, Khavjou OA, et al. Forecasting the future of cardiovascular disease in the United States: A policy statement from the American heart association. Circulation. 2011;123(8):933–944.
   PubMed Web of Science ®Google Scholar
• Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics—2015 update. Circulation. 2015;131(4):e29–e322.
   PubMed Web of Science ®Google Scholar
• National Institutes of Health. Morbidity & mortality – 2012 chart book on cardiovascular, lung and blood diseases. Bethseda: National Institutes of Health; 2012.
   Google Scholar
• Lamb CE, Ratner PH, Johnson CE, et al. Economic impact of workplace productivity losses due to allergic rhinitis compared with select medical conditions in the United States from an employer perspective. Curr Med Res Opin. 2006;22(6):1203–1210.
   PubMed Web of Science ®Google Scholar
• Heidenreich PA, Albert NM, Allen LA. Forecasting the impact of heart failure in the United States – a policy statement from the American heart association. Circ Heart Fail. 2013;6(3):609–619.
   Web of Science ®Google Scholar
• Ovbiagele B, Goldstein LB, Higashida RT, et al. Forecasting the future of stroke in the United States: a policy statement from the American heart association and American stroke association. Stroke. 2013;44(8):2361–2375.
   PubMed Web of Science ®Google Scholar
• Burke JF, Vijan S, Chekan LA, et al. Targeting high-risk employees may reduce cardiovascular racial disparities. Am J Manag Care. 2014;20(9):725–733.
   PubMed Web of Science ®Google Scholar
• Lang K, Korn JR, Simko RJ, et al. Development of an interactive model of the burden of future coronary heart disease from an employer perspective. J Occup Environ Med. 2010;52(9):851–857.
   PubMed Web of Science ®Google Scholar
• McBurney CR, Eagle KA, Kline-Rogers EM, et al. Work-related outcomes after a myocardial infarction. Pharmacotherapy. 2004;24(11):1515–1523.
   PubMed Web of Science ®Google Scholar
• Fukuoka Y, Dracup K, Takeshima M, et al. Effect of job strain and depressive symptoms upon returning to work after acute coronary syndrome. Soc Sci Med. 2009;68:1875–1881.
   PubMed Web of Science ®Google Scholar
• Epstein AJ, Groeneveld PW, Harhay MO, et al. Impact of minimally invasive surgery on medical spending and employee absenteeism. JAMA Surg. 2013;148(7):641–647.
   PubMed Web of Science ®Google Scholar
• Scafa F, Calsamiglia G, Tonini S, et al. Return to work after coronary angioplasty or heart surgery: A 5-year experience with the ‘cardioWork’ protocol. J Occup Environ Med. 2012;54(12):1545–1549.
   PubMed Web of Science ®Google Scholar
• Leeder S, Raymond S, Greenberg H, et al. A race against time – the challenge of cardiovascular disease in developing economies. New York: Columbia University; 2004.
   Google Scholar
• Lindgren P, Kahan T, Poulter N, et al. Utility loss and indirect costs following cardiovascular events in hypertensive patients: the ASCOT health economic substudy. Eur J Health Econ. 2007;8(1):25–30.
   PubMed Web of Science ®Google Scholar
• Maniadakis N, Kourlaba G, Cokkinos DV, et al. The economic burden of atherothrombosis in Greece: results from the THESIS study. Eur J Health Econ. 2013;14(4):655–665.
   PubMed Web of Science ®Google Scholar
• Gerzeli S, Tarricone R, Zolo P, et al. The economic burden of stroke in Italy. The ECLIPSE study: economic longitudinal incidence-based project for stroke evaluation. Neurol Sci. 2005;26:72–80.
   PubMed Web of Science ®Google Scholar
• Rossnagel K, Nolteb CH, Muller-Nordhorna J, et al. Medical resource use and costs of health care after acute stroke in Germany. Eur J Neurol. 2005;12:862–868.
   PubMed Web of Science ®Google Scholar
• Bolin K, Gip C, Mork AC, et al. Diabetes, healthcare cost and loss of productivity in Sweden 1987 and 2005 - A register-based approach. Diab Med. 2009;26(9):928–934.
   PubMed Web of Science ®Google Scholar
• Centre for Economics and Business Research (CEBR). The economic cost of cardiovascular disease from 2014-2020 in six European economies. London: Centre for Economics and Business Research; 2014.
   Google Scholar
• Gomez-De La Camara A, Pinilla-Dominguez P, Vazquez-Fernandez Del PS, et al. Costs resulting from premature mortality due to cardiovascular causes: A 20-year follow-up of the DRECE study. Rev Clin Esp. 2014;214(7):365–370.
   PubMed Web of Science ®Google Scholar
• Oliva-Moreno J. Loss of labour productivity caused by disease and health problems: what is the magnitude of its effect on Spain’s Economy? Eur J Health Econ. 2012;13(5):605–614.
   PubMed Web of Science ®Google Scholar
• Gouveia M, Costa J, Alarcao J, et al. Burden of disease and cost of illness of atrial fibrillation in Portugal. Rev Port Cardiol. 2015;34(1):1–11.
   PubMedGoogle Scholar
• Luengo-Fernandez R, Leal J, Gray A, et al. Cost of cardiovascular diseases in the United Kingdom. Heart. 2006;92(10):1384–1389.
   PubMed Web of Science ®Google Scholar
• Vlayen J, De BG, Peers J, et al. Atherosclerotic cardiovascular diseases in Belgium: A cost-of-illness analysis. Cardiovasc Drug Ther. 2008;22(6):487–494.
   PubMed Web of Science ®Google Scholar
• Saka O, McGuire A, Wolfe C. Cost of stroke in the United Kingdom. Age Ageing. 2009;38:27–32.
   PubMed Web of Science ®Google Scholar
• Lakic D, Tasic L, Kos M. Economic burden of cardiovascular diseases in Serbia. Vojnosanit Pregl. 2014;71:137–143.
   PubMed Web of Science ®Google Scholar
• Leal J, Luengo-Fernandez R, Gray A, et al. Economic burden of cardiovascular diseases in the enlarged European Union. Eur Heart J. 2006;27(13):1610–1619.
   PubMed Web of Science ®Google Scholar
• Calvo-Bonacho E, Ruilope LM, Sanchez-Chaparro MA, et al. Influence of high cardiovascular risk in asymptomatic people on the duration of cost and sick leave: results of the ICARIA study. Eur Heart J. 2014;35:299–306.
   PubMed Web of Science ®Google Scholar
• Van Der Burg LRA, Boonen A, Van Amelsvoort LGPM, et al. Effects of cardiovascular comorbidities on work participation in rheumatic diseases: A prospective cohort study among working individuals. Arthrit Care Res. 2014;66(1):157–163.
   Web of Science ®Google Scholar
• Hemingway H, Vahtera J, Virtanen M, et al. Outcome of stable angina in a working population: the burden of sickness absence. Eur J Cardiov Prev R. 2007;14(3):373–379.
   PubMedGoogle Scholar
• Kruse M, Sorensen J, Davidsen M, et al. Short and long-term labour market consequences of coronary heart disease: A register-based follow-up study. Eur J Cardiov Prev R. 2009;16(3):387–391.
   PubMedGoogle Scholar
• Isaaz K, Coudrot M, Sabry MH, et al. Return to work after acute ST-segment elevation myocardial infarction in the modern era of reperfusion by direct percutaneous coronary intervention. Arch Cardiovasc Dis. 2012;103(5):310–316.
   Web of Science ®Google Scholar
• Bhattacharyya MR, Perkins-Porras L, Whitehead DL, et al. Psychological and clinical predictors of return to work after acute coronary syndrome. Eur Heart J. 2007;28(2):160–165.
   PubMed Web of Science ®Google Scholar
• Sorensen J, Ploug UJ. The cost of diabetes-related complications: registry-based analysis of days absent from work. Economics Res Int. 2013;2013:618039.
   Google Scholar
• Vohra RS, Coughlin PA, McShane P, et al. Predictors of return to work following carotid endarterectomy. Brit J Surg. 2008;95(9):1111–1114.
   PubMed Web of Science ®Google Scholar
• Schofield D, Shrestha R, Percival R, et al. The personal and national costs of CVD: impacts on income, taxes, government support payments and GDP due to lost labour force participation. Int J Cardiol. 2013;166(1):68–71.
   PubMed Web of Science ®Google Scholar
• Finkelstein EA, Chay J, Bajpai S. The economic burden of self-reported and undiagnosed cardiovascular diseases and diabetes on Indonesian households. PLoS ONE. 2014;9(6):e99572.
   PubMedGoogle Scholar
• Wagner M, Lindgren P, Merikle E, et al. Economic evaluation of high-dose (80 mg/day) atorvastatin treatment compared with standard-dose (20 mg/day to 40 mg/day) simvastatin treatment in Canada based on the incremental decrease in end-points through aggressive lipid-lowering (IDEAL) trial. Can J Cardiol. 2009;25(11):e362–e369.
   PubMed Web of Science ®Google Scholar
• Hu S, Zhan L, Liu B, et al. Economic burden of individual suffering from atrial fibrillation-related stroke in China. Value Health Reg Issues. 2013;2(1):135–140.
   PubMedGoogle Scholar
• Access Economics. The shifting burden of cardiovascular disease in Australia. Canberra: Access Economics; 2005.
   Google Scholar
• Azambuja MIR, Foppa M, Maranhao MFDC, et al. Economic burden of severe cardiovascular diseases in Brazil: an estimate based on secondary data. Arq Bras Cardiol. 2008;91:148–171.
   PubMed Web of Science ®Google Scholar
• Bloom DE, Cafiero ET, Jané-Llopis E, et al. The global economic burden of noncommunicable diseases. Geneva: World Economic Forum; 2011.
   Google Scholar
• Chang HS, Kim HJ, Nam CM, et al. The socioeconomic burden of coronary heart disease in Korea. J Prev Med Public Health. 2012;45(5):291–300.
   PubMedGoogle Scholar
• Araujo DV, Tavares LR, Verissimo R, et al. Cost of heart failure in the unified health system. Arq Bras Cardiol. 2005;84:422–427.
   PubMedGoogle Scholar
• Access Economics. The economic costs of heart attack and chest pain (acute coronary syndrome). Canberra: Access Economics; 2009.
   Google Scholar
• Kim J, Lee E, Lee T, et al. Economic burden of acute coronary syndrome in South Korea: A national survey. BMC Cardiovasc Disord. 2013;13:1–8.
   PubMed Web of Science ®Google Scholar
• Kim HJ, Kim YA, Seo HY, et al. The economic burden of stroke in 2010 in Korea. J Korean Med Assoc. 2012;55(12):1226–1236.
   Web of Science ®Google Scholar
• Public Health Agency of Canada (PHAC). Economic burden of illness in Canada, 2005-2008. Ottawa: Public Health Agency of Canada; 2014.
   Google Scholar
• Zheng H, Ehrlich F, Amin J. Productivity loss resulting from coronary heart disease in Australia. Appl Health Econ Health Policy. 2010;8(3):179–189.
   PubMedGoogle Scholar
• Thanh NX, Chuck AW, Ohinmaa A, et al. Societal monetary benefits of pharmaceutical innovation: the case of ramipril in Canada. J Pharm Health Serv Res. 2013;4(4):195–201.
   Google Scholar
• Mirmohammadi SJ, Sadr-Bafghi SM, Mehrparvar AH, et al. Evaluation of the return to work and its duration after myocardial infarction. ARYA Atheroscler. 2014;10(3):137–140.
   PubMedGoogle Scholar
• Worcester MU, Elliott PC, Turner A, et al. Resumption of work after acute coronary syndrome or coronary artery bypass graft surgery. Heart Lung Circ. 2014;23(5):444–453.
   PubMed Web of Science ®Google Scholar
• Koopmanschap MA, Van Ineveld BM. Towards a new approach for estimating indirect costs of disease. Soc Sci Med. 1992;34(9):1005–1010.
   PubMed Web of Science ®Google Scholar